Cargando…

Evaluation of a Prognostic Epigenetic Classification System in Chronic Lymphocytic Leukemia Patients

BACKGROUND: Methylation at 5 CpG sites was previously shown to classify chronic lymphocytic leukemia (CLL) into 3 prognostic subgroups. Here, we aimed to validate the marker set in an additional cohort and to evaluate its clinical utility for CLL patient stratification. METHODS: We evaluated this ep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grimm, Christina, Herling, Carmen Diana, Komnidi, Anastasia, Hussong, Michelle, Kreuzer, Karl-Anton, Hallek, Michael, Schweiger, Michal R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793417/ https://www.ncbi.nlm.nih.gov/pubmed/35095271 http://dx.doi.org/10.1177/11772719211067972

Ejemplares similares

Comprehensive Analysis of Disease-Related Genes in Chronic Lymphocytic Leukemia by Multiplex PCR-Based Next Generation Sequencing
por: Vollbrecht, Claudia, et al.
Publicado: (2015)

Proteogenomics refines the molecular classification of chronic lymphocytic leukemia
por: Herbst, Sophie A., et al.
Publicado: (2022)

Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
por: Herling, Carmen D., et al.
Publicado: (2018)

Flow Cytometry and Polymerase Chain Reaction-Based Analyses of Minimal Residual Disease in Chronic Lymphocytic Leukemia
por: Uhrmacher, Sabrina, et al.
Publicado: (2010)

Towards control of chronic lymphocytic leukemia using chemotherapy-free combinations
por: Hallek, Michael
Publicado: (2018)

Altered DNA Methylation Profiles in SF3B1 Mutated CLL Patients
por: Pacholewska, Alicja, et al.
Publicado: (2021)

Sequential and combination treatments with novel agents in chronic lymphocytic leukemia
por: Fürstenau, Moritz, et al.
Publicado: (2019)

The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab
por: Kreuzer, Karl-Anton, et al.
Publicado: (2019)

Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia
por: Knittel, Gero, et al.
Publicado: (2017)

High lymphoid enhancer-binding factor-1 expression is associated with disease progression and poor prognosis in chronic lymphocytic leukemia
por: Erdfelder, Felix, et al.
Publicado: (2010)

Survival of patients with chronic lymphocytic leukemia before and after the introduction of chemoimmunotherapy in Germany
por: Kajüter, Hiltraud, et al.
Publicado: (2021)

Loss of Msh2 and a single-radiation hit induce common, genome-wide, and persistent epigenetic changes in the intestine
por: Herberg, Maria, et al.
Publicado: (2019)

Epigenetic evolution and lineage histories of chronic lymphocytic leukemia
por: Gaiti, Federico, et al.
Publicado: (2019)

Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy
por: Al-Sawaf, Othman, et al.
Publicado: (2017)

The bromodomain protein BRD4 regulates splicing during heat shock
por: Hussong, Michelle, et al.
Publicado: (2017)

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
por: von Tresckow, Julia, et al.
Publicado: (2022)

T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective
por: Peters, Fleur S., et al.
Publicado: (2021)

Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients
por: Bloehdorn, Johannes, et al.
Publicado: (2021)

Prognostic Role of Lymphocyte/Monocyte Ratio in Chronic Lymphocytic Leukemia
por: Yokus, Osman, et al.
Publicado: (2020)

A rare case of t(11;22) in a mantle cell lymphoma like B-cell neoplasia resulting in a fusion of IGL and CCND1: case report
por: Rocha, Cristiano Krings, et al.
Publicado: (2011)

S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies
por: Thomalla, D., et al.
Publicado: (2022)

Investigating epigenetic effects of activation-induced deaminase in chronic lymphocytic leukemia
por: Schubert, Maria, et al.
Publicado: (2018)

Epigenetic and genetic alterations and their influence on gene regulation in chronic lymphocytic leukemia
por: Huang, Di, et al.
Publicado: (2017)

Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways
por: Abruzzo, Lynne V., et al.
Publicado: (2018)

Prognostic Value of the miR-17~92 Cluster in Chronic Lymphocytic Leukemia
por: Chocholska, Sylwia, et al.
Publicado: (2023)

The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia
por: Rusyn, Lisa, et al.
Publicado: (2022)

Prognostic Potential of Galectin-9 mRNA Expression in Chronic Lymphocytic Leukemia
por: Bojarska-Junak, Agnieszka, et al.
Publicado: (2023)

Genomic landscape characterization of large granular lymphocyte leukemia with a systems genetics approach
por: Coppe, A, et al.
Publicado: (2017)

First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab
por: Schweighofer, Carmen Diana, et al.
Publicado: (2010)

A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies
por: Sharman, Jeffrey P., et al.
Publicado: (2022)

Micro-RNA networks in T-cell prolymphocytic leukemia reflect T-cell activation and shape DNA damage response and survival pathways
por: Braun, Till, et al.
Publicado: (2020)

Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group
por: Jaramillo, Sonia, et al.
Publicado: (2019)

S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLL12 TRIAL
por: Langerbeins, Petra, et al.
Publicado: (2023)

The use of circulating cell-free tumor DNA in routine diagnostics of metastatic melanoma patients
por: Knuever, Jana, et al.
Publicado: (2020)

T cells in chronic lymphocytic leukemia: can they fight?
por: Vardi, Anna, et al.
Publicado: (2017)

T Cell Defects and Immunotherapy in Chronic Lymphocytic Leukemia
por: Vlachonikola, Elisavet, et al.
Publicado: (2021)

Phenotypic alteration of CD8(+) T cells in chronic lymphocytic leukemia is associated with epigenetic reprogramming
por: Wu, Jiazhu, et al.
Publicado: (2016)

Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO)
por: Cramer, Paula, et al.
Publicado: (2020)

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tomqokk6711p8bee8nfq77tbck